GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Genmab A/S (GMAB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has strong financial performance and positive analyst sentiment, the technical indicators suggest a bearish trend, and there are no immediate catalysts or proprietary trading signals to justify an entry point right now. Holding off for a better entry point or further positive developments would be prudent.
The MACD is negatively expanding (-0.406), indicating bearish momentum. The RSI is at 18.097, signaling an oversold condition, but this does not guarantee an immediate reversal. Moving averages are converging, showing no clear trend direction. The stock is trading below the pivot level (31.457) and near its first support level (29.91), with further downside risk to S2 (28.954).
Analysts remain bullish with multiple buy ratings and raised price targets, highlighting significant growth potential in 2026 due to three major catalysts.
Strong financial performance in Q3 2025, with revenue up 25.25% YoY and net income up 115.59% YoY.
Recent failure of the EPCORE DLBCL-1 trial's primary endpoint, which could weigh on sentiment.
The stock has a bearish technical setup, with no immediate trading signals or strong upward momentum.
In Q3 2025, Genmab demonstrated robust financial growth: Revenue increased by 25.25% YoY to $1.022 billion, net income surged by 115.59% YoY to $401 million, and EPS grew by 121.23% YoY to 6.46. However, gross margin slightly declined by -0.82% YoY to 94.32%.
Analysts are optimistic about Genmab, with consistent buy ratings and price targets ranging from $38.50 to $48. Recent updates highlight a 'catalyst-rich' fiscal 2026, with potential $2B peak sales opportunities in key markets. Despite the EPCORE DLBCL-1 trial setback, analysts remain confident in the company's long-term prospects.
